NCT00617617 - The Specific Role of Isoflavones in Reducing Prostate Cancer Risk | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Prostate Cancer

Interventions

DIETARY_SUPPLEMENT

Prevastein HC®

Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.

OTHER

Placebo

Control Group - Control Group participants will receive an identical placebo.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa